Market Cap 3.46B
Revenue (ttm) 627.24M
Net Income (ttm) -177.03M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 37.25
Profit Margin -28.22%
Debt to Equity Ratio 0.31
Volume 1,418,100
Avg Vol 2,509,996
Day's Range N/A - N/A
Shares Out 184.69M
Stochastic %K 42%
Beta 0.07
Analysts Strong Sell
Price Target $58.23

Company Profile

Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candida...

Industry: Biotechnology
Sector: Healthcare
Phone: 737 317 5050
Address:
2101 Cottontail Lane, Somerset, United States
hEnlightment
hEnlightment Mar. 15 at 7:41 PM
$LEGN I don't mind the current downtrend. Make it like 17$ and I"ll double my position.
0 · Reply
kiwiSurfer
kiwiSurfer Mar. 15 at 3:22 PM
$LEGN bingo!
0 · Reply
Tigerpicko
Tigerpicko Mar. 13 at 9:40 AM
🚨 $LEGN Short Squeeze Alert! 🚨 • Short Interest: 20,045,763 shares • Days to Cover: 14.5 🕒 • Off-Exchange Short Volume Ratio: • Mar 6: 66% • Mar 9: 63% • Mar 10: 46% • Mar 11: 56% • Mar 12: 69.8% 🔥 • Borrow Fee Rate: ~0.41-0.42% (cheap to short, heavy short pressure) 💥 With nearly 70% of yesterdays volume shorted and huge institutional positioning in dark pools, any buying catalyst could trigger a massive squeeze. 🚀 Eyes on the $LEGN chart—this is a short squeeze setup of the year! 📈 Bullish move incoming? Stay ready!
0 · Reply
Tigerpicko
Tigerpicko Mar. 12 at 8:04 PM
$LEGN 🔬📉➡️📈 $LEGN closed today $19.05 (-6.02%) on about 1.32M volume. That’s still not heavy selling volume, which suggests this move was more short-term traders taking profits and shaking out weak hands, not institutions exiting. The options setup into the Mar 20 expiration still leans bullish: 📊 Call positioning • $20 calls: 1,112 open interest • $22.50 calls: 449 open interest • $25 calls: 206 open interest That creates a stacked call ladder above current price. Key levels now: Support ➡️ $18$18.50 Breakout trigger ➡️ $20 If $LEGN pushes back above $20, the next levels could come quickly: ➡️ $22.50 ➡️ $25 ➡️ $27.50 Analysts recently maintained Overweight / Outperform ratings on Legend Biotech Corporation, so the long-term thesis hasn’t changed. Low float biotech + heavy call positioning = one strong green session can flip sentiment fast. Watching for volume expansion and a reclaim of $20 — that’s when momentum traders usually step back
0 · Reply
KY3000
KY3000 Mar. 12 at 7:54 PM
$LEGN I don’t think they can hold this down for much longer?
0 · Reply
Tigerpicko
Tigerpicko Mar. 12 at 6:08 PM
$LEGN Options setup is screaming bullish 📊 March 20 chain showing • 1,112 calls stacked at $20 • Heavy upside positioning at $22.5 and $25 • Puts mostly far below price Market makers are sitting on a gamma magnet at $20. With Carvykti sales ramping and analysts reiterating Overweight, a break over $20 could trigger a fast move. Targets: 🎯 $22.50 🎯 $25 🎯 $30 if squeeze builds $LEGN $JNJ
0 · Reply
GeniusLoci
GeniusLoci Mar. 12 at 4:42 PM
$DAWN Let go of DAWN for a 212% short-term gain. Recycled the proceeds into $LEGN and $VSTM
1 · Reply
Tigerpicko
Tigerpicko Mar. 12 at 10:11 AM
$LEGN 🚀 Calls $22.5–$25 heating up, almost no puts → minimal downside, shorts trapped 💣 Analysts targets $62$86! Carvykti + $JNJ driving explosive growth. Low $20S now → $25$30 next! Momentum incoming 💥 $LEGN $JN
0 · Reply
Tigerpicko
Tigerpicko Mar. 12 at 9:57 AM
$LEGN 🚀💥 CAR‑T Carvykti booming with $JNJ backing! Analysts targets $62$86, low $20S now → huge upside potential. Calls $22.5–$25 heating up, shorts still trapped 💣 Momentum could ignite fast! $LEGN $JNJ $BULLISH.X $STOCKTWITS
0 · Reply
Bornjever
Bornjever Mar. 11 at 11:24 PM
$LEGN actually I am sorry I exaggerated and I said they sold almost one billion plus for 18 dollar stock because I said it was over one billion and it was actually 1.9 billion because things they were saying is they were almost out money at the end of the year last year and losing tons of money and not going to achieve sales for last year and absolutely going down this year. Only thing that was consistent was the lying on almost every point.
1 · Reply
Latest News on LEGN
Top 3 Health Care Stocks You'll Regret Missing This Quarter

Dec 18, 2025, 7:00 AM EST - 3 months ago

Top 3 Health Care Stocks You'll Regret Missing This Quarter

INSM TEM


Cancer Study Buoys These Small Biotechs

Dec 9, 2025, 3:31 PM EST - 3 months ago

Cancer Study Buoys These Small Biotechs

ACLX TERN


Legend Biotech: Is Carvykti Changing Cancer Treatment Forever?

Nov 25, 2025, 2:38 PM EST - 3 months ago

Legend Biotech: Is Carvykti Changing Cancer Treatment Forever?


Legend Biotech Corporation (LEGN) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 12:51 PM EST - 4 months ago

Legend Biotech Corporation (LEGN) Q3 2025 Earnings Call Transcript


Legend Biotech Appoints Carlos Santos as Chief Financial Officer

Aug 18, 2025, 8:00 AM EDT - 7 months ago

Legend Biotech Appoints Carlos Santos as Chief Financial Officer


Legend Biotech Corporation (LEGN) Q1 2025 Earnings Call Transcript

May 13, 2025, 11:15 AM EDT - 10 months ago

Legend Biotech Corporation (LEGN) Q1 2025 Earnings Call Transcript


Legend Biotech: The Story Brightens

Dec 5, 2024, 2:14 PM EST - 1 year ago

Legend Biotech: The Story Brightens


Legend Biotech Appoints Alan Bash as President of CARVYKTI®

Nov 4, 2024, 7:30 AM EST - 1 year ago

Legend Biotech Appoints Alan Bash as President of CARVYKTI®


Legend Biotech to set up new R&D facility in Philadelphia

Oct 3, 2024, 7:41 AM EDT - 1 year ago

Legend Biotech to set up new R&D facility in Philadelphia


hEnlightment
hEnlightment Mar. 15 at 7:41 PM
$LEGN I don't mind the current downtrend. Make it like 17$ and I"ll double my position.
0 · Reply
kiwiSurfer
kiwiSurfer Mar. 15 at 3:22 PM
$LEGN bingo!
0 · Reply
Tigerpicko
Tigerpicko Mar. 13 at 9:40 AM
🚨 $LEGN Short Squeeze Alert! 🚨 • Short Interest: 20,045,763 shares • Days to Cover: 14.5 🕒 • Off-Exchange Short Volume Ratio: • Mar 6: 66% • Mar 9: 63% • Mar 10: 46% • Mar 11: 56% • Mar 12: 69.8% 🔥 • Borrow Fee Rate: ~0.41-0.42% (cheap to short, heavy short pressure) 💥 With nearly 70% of yesterdays volume shorted and huge institutional positioning in dark pools, any buying catalyst could trigger a massive squeeze. 🚀 Eyes on the $LEGN chart—this is a short squeeze setup of the year! 📈 Bullish move incoming? Stay ready!
0 · Reply
Tigerpicko
Tigerpicko Mar. 12 at 8:04 PM
$LEGN 🔬📉➡️📈 $LEGN closed today $19.05 (-6.02%) on about 1.32M volume. That’s still not heavy selling volume, which suggests this move was more short-term traders taking profits and shaking out weak hands, not institutions exiting. The options setup into the Mar 20 expiration still leans bullish: 📊 Call positioning • $20 calls: 1,112 open interest • $22.50 calls: 449 open interest • $25 calls: 206 open interest That creates a stacked call ladder above current price. Key levels now: Support ➡️ $18$18.50 Breakout trigger ➡️ $20 If $LEGN pushes back above $20, the next levels could come quickly: ➡️ $22.50 ➡️ $25 ➡️ $27.50 Analysts recently maintained Overweight / Outperform ratings on Legend Biotech Corporation, so the long-term thesis hasn’t changed. Low float biotech + heavy call positioning = one strong green session can flip sentiment fast. Watching for volume expansion and a reclaim of $20 — that’s when momentum traders usually step back
0 · Reply
KY3000
KY3000 Mar. 12 at 7:54 PM
$LEGN I don’t think they can hold this down for much longer?
0 · Reply
Tigerpicko
Tigerpicko Mar. 12 at 6:08 PM
$LEGN Options setup is screaming bullish 📊 March 20 chain showing • 1,112 calls stacked at $20 • Heavy upside positioning at $22.5 and $25 • Puts mostly far below price Market makers are sitting on a gamma magnet at $20. With Carvykti sales ramping and analysts reiterating Overweight, a break over $20 could trigger a fast move. Targets: 🎯 $22.50 🎯 $25 🎯 $30 if squeeze builds $LEGN $JNJ
0 · Reply
GeniusLoci
GeniusLoci Mar. 12 at 4:42 PM
$DAWN Let go of DAWN for a 212% short-term gain. Recycled the proceeds into $LEGN and $VSTM
1 · Reply
Tigerpicko
Tigerpicko Mar. 12 at 10:11 AM
$LEGN 🚀 Calls $22.5–$25 heating up, almost no puts → minimal downside, shorts trapped 💣 Analysts targets $62$86! Carvykti + $JNJ driving explosive growth. Low $20S now → $25$30 next! Momentum incoming 💥 $LEGN $JN
0 · Reply
Tigerpicko
Tigerpicko Mar. 12 at 9:57 AM
$LEGN 🚀💥 CAR‑T Carvykti booming with $JNJ backing! Analysts targets $62$86, low $20S now → huge upside potential. Calls $22.5–$25 heating up, shorts still trapped 💣 Momentum could ignite fast! $LEGN $JNJ $BULLISH.X $STOCKTWITS
0 · Reply
Bornjever
Bornjever Mar. 11 at 11:24 PM
$LEGN actually I am sorry I exaggerated and I said they sold almost one billion plus for 18 dollar stock because I said it was over one billion and it was actually 1.9 billion because things they were saying is they were almost out money at the end of the year last year and losing tons of money and not going to achieve sales for last year and absolutely going down this year. Only thing that was consistent was the lying on almost every point.
1 · Reply
KY3000
KY3000 Mar. 11 at 9:44 PM
$LEGN this hasn’t caught the biotech wave
1 · Reply
erevnon
erevnon Mar. 11 at 3:09 PM
RBC Capital maintains Legend Biotech $LEGN at Outperform and lowers the price target from $66 to https://marketsblock.com/stock-upgrades-and-downgrades/
1 · Reply
Tigerpicko
Tigerpicko Mar. 11 at 9:46 AM
$LEGN ⏳ Earnings in ✅ Carvykti ramp ✅ Analysts likely updating forecasts next 1–3 weeks. Big re-ratings possible late spring 2026 💎🔥 Stay tuned! 📈
0 · Reply
Tigerpicko
Tigerpicko Mar. 11 at 9:43 AM
$LEGN 🚀 Trading $19.56 vs fair value ~$39.81 💎 Institutional buying + Carvykti ramp fueling momentum. Earnings confirm revenue growth & narrowing losses. Next 2 weeks = 🔥 squeeze & re-rating potential 📈 $24$28, $30+ if pressure accelerates!
0 · Reply
Tigerpicko
Tigerpicko Mar. 11 at 9:40 AM
$LEGN 🚀 Earnings beat ✅ Institutional buying 💰 Puts gone, calls not fully priced 📈 Next 2 weeks = momentum building, potential squeeze 💎💥 Eyes on $24$28, $30+ if velocity hits 🔥
0 · Reply
Tigerpicko
Tigerpicko Mar. 11 at 9:38 AM
$LEGN 🚀 All puts up to $35 are gone—zero open interest, zero bids/asks. Bears have fully exited. Calls $10$30? Also nearly zero open interest. The market hasn’t even priced in the upside yet. After this earnings beat and the Carvykti ramp with J&J, downside hedges are gone and bullish momentum is ready to run. 💎📈 Momentum build = squeeze potential rising. Eyes on $LEGN! 🔥
0 · Reply
KY3000
KY3000 Mar. 10 at 8:15 PM
$LEGN genscript biotech considering a dividend, this is starting to stink
0 · Reply
KY3000
KY3000 Mar. 10 at 5:57 PM
$LEGN can we close above 20$ for my sanity
1 · Reply
PencilNeckGeek
PencilNeckGeek Mar. 10 at 5:31 PM
$LEGN This has been having some pretty big intraday price swings
1 · Reply
hEnlightment
hEnlightment Mar. 10 at 5:26 PM
$LEGN It's undervalued. Still an excellent price to jump in! Very
0 · Reply
Bornjever
Bornjever Mar. 10 at 3:13 PM
$LEGN you understand the 22 million shorts are trapped because this company crushed earnings -.18 to +.01 and all 900 million in cash whereas the detractors were saying they were going to need to dilute and this thing about no efficacy of drugs is completely false so do not sell as this will not stay down at this pathetic level. VERY
2 · Reply
Tigerpicko
Tigerpicko Mar. 10 at 2:57 PM
$LEGN some short-term selling after earnings, but that’s actually very common after a big biotech report. A lot of traders take quick profits after the run-up, which can create temporary pressure. What matters is the underlying story from Legend Biotech’s results, and it was very strong. • CARVYKTI Q4 sales $555M (+66% YoY) • Global expansion to 14 markets / 294 treatment sites • Manufacturing scaling 10,000 → 20,000 doses planned with Johnson & Johnson • Majority of patients now treated earlier in therapy (~65%) expanding the addressable market • Company expects full profitability in 2026 Short-term volatility is normal after earnings, but the fundamentals here continue to improve rapidly. If the market starts focusing on the manufacturing scale and accelerating demand, this story could look very different over the coming weeks. Watching closely.
0 · Reply